Alveolar soft part sarcoma
Jump to navigation
Jump to search
| Section editor | |
|---|---|
 |
Elizabeth J. Davis, MD Vanderbilt University Nashville, TN, USA |
Note: this is a rare cancer, see this page for more information. These are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.
1 regimens on this page
4 variants on this page
|
Guidelines
NCCN
- NCCN does not have guidelines at this granular level; please see NCCN Guidelines - Soft Tissue Sarcoma.
All lines of therapy
Atezolizumab monotherapy
Regimen variant #1, q3wk
| FDA-recommended dose |
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Chen et al. 2023 (Study ML39345) | 2017-04 to 2022-07 | Phase 2 (RT) |
Regimen variant #2, q2wk
| FDA-recommended dose |
Regimen variant #3, q4wk
| FDA-recommended dose |
Regimen variant #4, pediatric dosing
| FDA-recommended dose |
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Chen et al. 2023 (Study ML39345) | 2017-04 to 2022-07 | Phase 2 (RT) |
Immunotherapy
- Atezolizumab (Tecentriq) 15 mg/kg (maximum dose of 1200 mg) IV once on day 1
21-day cycles
References
- Study ML39345: Chen AP, Sharon E, O'Sullivan-Coyne G, Moore N, Foster JC, Hu JS, Van Tine BA, Conley AP, Read WL, Riedel RF, Burgess MA, Glod J, Davis EJ, Merriam P, Naqash AR, Fino KK, Miller BL, Wilsker DF, Begum A, Ferry-Galow KV, Deshpande HA, Schwartz GK, Ladle BH, Okuno SH, Beck JC, Chen JL, Takebe N, Fogli LK, Rosenberger CL, Parchment RE, Doroshow JH. Atezolizumab for Advanced Alveolar Soft Part Sarcoma. N Engl J Med. 2023 Sep 7;389(10):911-921. link to original article PubMed NCT03141684